Effect of valsartan on the expression of Endothelin-1 in the retinea of diabetic rats

doi:10.3877/cma.j.issn.2095-2007.2017.02.004

Abstract

Abstract:

Objective

We aimed to observe the changes of the ET-1 protein expression in the retinea of diabetic rats which were treated by Valsartan, to reveal the therapeutical mechanism of suppressing the rennin-angitensin system in the diabetic retinopathy.

Methods

115 male Wistar rats were divided into normal, diabetes mellitus and treatment group randomly. The control group consisted of 40 rats, the experimental group consisted of 40 rats and the blank control group consisted of 35 rats. An animal model of diabetes was established. The control group and the experimental group were injected with the same dose of citric acid buffer solution in the same time by 65 mg/kg weight intraperitoneal injection of STZ solution with a concentration of 1%. Fasting blood glucose level of 16.65 mmol/L as a successful model. After the establishment of the model, the diabetes mellitus group was treated with Valsatan 24 mg/(kg·d), the other two groups are given distilled water. All the rats were normal bred. 2, 4 and 6 weeks after rat modal of diabetes, pluck eyeball after anesthesia. ADP enzymohisto-chemistry stain method of retinal stretched preparation was used to observe the change of retinal blood vessels. The immunohistochemistry method was used to measure the expression of ET-1 in the retina. The average integral optical density value of ET-1 was expressed as mean±standard deviation(±s). The two factor repeated measures analysis of variance was used to compare the differences between different groups and at different time points. The difference was statistically significant, and the Student-NewMan-Keuls method was used to compare the differences.

Results

The retinal optical microscopic observation showed that the level of blank control group rat retinal tissue structure is clear, the blank cells in each layer arranged, cell staining uniform and regular shape; the control group 6 weeks retinal tissue structure of rats, ganglion cells were arranged disorder, reducing the number of cells and the thinning of the retina; retinal tissue structure in experimental group 6 weeks in rats, and no obvious abnormalities. Normal rats have normal retinal blood vessels and Capillary tube was uniform. Diabetic rats had abnomal change in retinal vascular in the 6th week. 6 weeks of treatment group in rats had nonsignificant abnormal vascular. There was significant difference in ET-1 expression between the three groups of blank control group, control group and experimental group (F_group =95.15, P<0.05). The expression of ET-1 in diabetic rats increased gradually with the progression of the disease, the control group>the experimental group>the blank control group, the difference was statistically significant (t=-13.45, -9.47, 8.57; P<0.05). At different time points, 6 weeks>4 weeks>2 weeks, the difference was statistically significant (F_time=72.12, P<0.05). The expression levels of ET-1 in the retina of the control group were compared at different time points, the difference was statistically significant (t=-7.63, -12.85, -7.32; P<0.05). The expression levels of ET-1 in the retina of experimental group were compared with each other at different time points, the difference was statistically significant (t=-4.03, -10.62, -7.68; P<0.05).

Conclusion

Valsartan can reduce ET-1 in the retina of diabetic rat. Therefore, it is said to have treatment of diabetic retinopathy.

Key words: Diabetes mellitus, Retina, Valsartan, Endothelin-1

Xiaolong Chen, Fang Li. Effect of valsartan on the expression of Endothelin-1 in the retinea of diabetic rats[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2017, 07(02): 72-77.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2017.02.004

https://zhykyxzz.cma-cmc.com.cn/EN/Y2017/V07/I02/72

Figures/Tables 3

References 48

[1]	Sjølie AK. Prospects for angiotensin receptor blockers in diabetic retinopathy[J]. Diabetes Research & Clinical Practice, 2007, 76,(3):31-39.
[2]	Simó R, Lecube A, Segura RM, et al. Free insulin growth factor－I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy[J]. Am J Ophthalmol, 2002, 134(3):376-382.
[3]	Clermont A, Bursell SE, Feener EP. Role of the angiotensin Ⅱ type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond[J]. Journal of Hypertension, 2006, 24(1):73-80.
[4]	Yoshida A, Yoshida SA, Ishibashi T, et al. Role of NF－kappaB－mediated interleukin－8 expression in intraocular neovascularization[J]. Invest Ophthalmol Vis Sci, 1998, 39(7):1097-1106.
[5]	Romeo G, Liu WH, Asnaghi V, et al. Activation of nuclear factor－kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes[J]. Diabetes, 2002, 51(7):2241-2248.
[6]	安娜. 诱导型2型糖尿病动物模型的研究进展[J]. 中华实用医药杂志，2007,7(8):686-689.
[7]	黄松，冼苏. 糖尿病动物模型研究现状及进展[J]. 广西医学，2002,24(1):46-48.
[8]	Mohamed AK, Bierhaus A, Schiekofer S, et al. The role of oxidative stress and NF－kappaB activation in late diabetic complications[J]. Biofactors, 1999, 10(2):157-167.
[9]	Ciulla TA, Pawlyk BS, Harris A, et al. Endothelin－1－mediated retinal artery vasospasm and the rabbit electroretinogram[J]. Journal of Ocular Pharmacology & Therapeutics, 2000, 16(4):393-398.
[10]	杨亦彬，张翥，苏克亮，等. 链脲佐菌素诱导大鼠糖尿病肾病模型的方法学探讨[J]. 华西医学，2005,20(2):299-300.
[11]	Joost HG, Al－Hasani H, Schurmann A. Animal Models in Diabetes Research[J]. Archives of Medical Research, 1994, 25(4):591-375.
[12]	Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J]. Nature, 1999, 332(3):411-415.
[13]	Insel JR, Kolterman OG, Saekow M, et al. Short－term regulation of insulin receptor affinity in man[J]. Diabetes, 1980, 29(2):132-139.
[14]	Masiello P, De PA, Bergamini E. Age－dependent changes in the sensitivity of the rat to a diabetogenic agent (streptozotocin)[J]. 1975, 96(3):787-789.
[15]	施沃栋，王志良，罗敏，等. 链脲佐菌素诱发糖尿病大鼠模型视网膜形态学改变的观察[J]. 眼科新进展，2008,28(8):583-585.
[16]	何剑峰，杜娟，唐柳萍，等. 糖尿病大鼠视网膜微血管变化与血液流变学的关系[J]. 中国组织工程研究，2005,9(31):93-95.
[17]	Yanagisawa M, Inoue A, Ishikawa T, et al. Primary Structure, Synthesis, and Biological Activity of Rat Endothelin, an Endothelium－Derived Vasoconstrictor Peptide[J]. Proceedings of the National Academy of Sciences, 1988, 85(18):6964.
[18]	曹文捷，周英华. ET21的眼科研究进展[J]. 国际眼科杂志，2007,7(3):782-783.
[19]	康平，路晖，王作芬，等. 糖尿病视网膜病变患者视网膜电图震荡电位与荧光素眼底血管造影的对比研究[J]. 眼科，2010,19(4):283-284.
[20]	Fouda AY, Artham S, Elremessy AB, et al. Renin－angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence[J]. Clinical Science, 2016, 130(4):221.
[21]	Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin－angiotensin system: new data from the DIRECT study programme[J]. Eye, 2010, 24(1):1-6.
[22]	张雁冰，成霄黎. 血管内皮生长因子与糖尿病视网膜病变的研究进展[J]. 山西医药杂志，2006,35(8):714-717.
[23]	Takagi C, Bursell SE, Lin YW, et al. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin－1[J]. Invest Ophthalmol Vis Sci, 1996, 37(12):2504-2518.
[24]	Honoré JC, Fecteau MH, Brochu I, et al. Concomitant antagonism of endothelial and vascular smooth muscle cell ETB receptors for endothelin induces hypertension in the hamster[J]. Ajp Heart & Circulatory Physiology, 2005, 289(3):1258-1264.
[25]	Iannaccone A, Letizia C, Pazzaglia S, et al. Plasma endothelin－1 concentrations in patients with retinal vein occlusions[J]. British Journal of Ophthalmology, 1998, 82(5):498-503.
[26]	Kawamura M, Ohgawara H, Naruse M，et al. Plasma Endothelin Levels in Diabetic Patients with Retinopathy[J]. Journal of the Japan Diabetes Society, 1993, 36(2):125-128.
[27]	Deng D, Evans T, Mukherjee K, et al. Diabetes－induced vascular dysfunction in the retina: role of endothelins[J]. Diabetologia, 1999, 42(10):1228-1234.
[28]	Kim TW, Kang KB, Choung HK, et al. Elevated glutamate levels in the vitreous body of an in vivo model of optic nerve ischemia[J]. Archives of Ophthalmology, 2000, 118(4):533-536.
[29]	Takashima Y, Takagi H, Takahashi M, et al. Endothelin protein expression in tear glands of the rabbit[J]. Current Eye Research, 1996, 15(7):768-773.
[30]	黄敬泽，张闿珍，王健. 外周血循环内皮细胞、血浆内皮素与糖尿病视网膜病变的关系[J]．中华眼底病杂志，2003,3(16):166-168.
[31]	Naidoo V, Mahabeer R, Raidoo DM. Cellular distribution of endothelin－1 mRNA in human brain by in situ RT－PCR[J]. Metabolic Brain Disease, 2001, 16(3):207-218.
[32]	钟惠菊，郭丽娟. 糖尿病视网膜病变者血浆内皮素水平及导昇明治疗后的变化[J]. 湖南医科大学学报，1997,22(1):56-58.
[33]	管怀进，龚启荣，田明华. 视网膜静脉阻塞发病机理的探讨[J]．实用眼科杂志，1993,11(3):155-158.
[34]	Shoji N, Oshika T, Masuda K. Endothelin－1 and intraocular inflammation in pigmented rabbit eyes[J]. Jpn J Ophthalmol, 1997, 41(3):150-153.
[35]	卢筱华，冯烈，许敏华. 氯沙坦对糖尿病大鼠肾脏保护作用的探讨[J]. 中华肾脏病杂志，2000,16(2):182-185.
[36]	杜红阳，刘丹，付海燕. 血浆与2型糖尿病视网膜病变相关关系[J]. 眼科新进展，2006,26(9):687.
[37]	Rabelink TJ, Bakris GL. The renin－angiotensin system in diabetic nephropathy: the endothelial connection[J]. Mineral & Electrolyte Metabolism, 1998, 24(6):381-388.
[38]	Evans JJ, Youssef AH, Yandle TG, et al. Endothelin－1 directly modulates its own secretion: studies utilising the cell immunoblot technique[J]. Regulatory Peptides, 2003, 113(1):149-153.
[39]	Bicket DP. Using ACE inhibitors appropriately[J]. American Family Physician, 2002, 66(3):461-468.
[40]	Takahashi K, Komaru T, Takeda S, et al. Nitric oxide inhibition unmasks ischemic myocardium－derived vasoconstrictor signals activating endothelin type A receptor of coronary microvessels[J]. Am J Physiol Heart Circ Physiol, 2005, 289(1):H85-H91.
[41]	Johnström P, Fryer TD, Richards HK, et al. Positron emission tomography using 18F－labelled endothelin－1 reveals prevention of binding to cardiac receptors owing to tissue－specific clearance by ET B receptors in vivo[J]. British Journal of Pharmacology, 2005, 144(1):115-121.
[42]	Lam HC, Lee JK, Lu CC, et al. Roie of endothelin in doabetic retinopathy[J]. Curr Vasc Phannacol, 2003, 1(3):243-250.
[43]	Haefliger IO, Meyer P, Flammer J, et al. The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology[J]. Surv Ophthamol, 1994, 39(2):123-130.
[44]	Bursell SE, Clermont AC, Oren B, et al. The in vivo effect of endothelins on retinal circulation in nondiabetic and diabetic rats[J]. Invest Ophthalmol Vis Sci, 1995, 36(3):596-607.
[45]	Mcauley DF, Mcgurk C, Nugent AG, et al. Vasoconstriction to endothelin－1 is blunted in non－insulin－dependent diabetes: a dose－response study[J]. Journal of Cardiovascular Pharmacology, 2000, 36(2):203-208.
[46]	Rajagopalan S, Laursen JB, Borthayre A, et al. Role for endothelin－1 in angiotensin Ⅱ－mediated hypertension[J]. Hypertension, 1997, 30(1):29-34.
[47]	刘志文，刘春燕. 血管紧张素Ⅱ受体拮抗剂在糖尿病肾病中的应用[J]. 国际内分泌代谢杂志，2000,20(1):45-47.
[48]	Phipps JA, Wilkinsonberka JL, Fletcher EL. Retinal dysfunction in diabetic ren－2 rats is ameliorated by treatment with valsartan but not atenolol[J]. Invest Ophthalmol Vis Sci, 2007, 48(2):927-934.

组别	积分光密度值
组别	2周	4周	6周
空白对照组	16.10±11.01	15.35±8.38	15.22±4.71
对照组	21.20±11.84	60.19±12.95^ab	114.21±22.71^ab
实验组	18.14±9.67	32.37±8.10^a	64.03±12.22^a

组别	积分光密度值
组别	2周	4周	6周
空白对照组	16.10±11.01	15.35±8.38	15.22±4.71
对照组	21.20±11.84	60.19±12.95^ab	114.21±22.71^ab
实验组	18.14±9.67	32.37±8.10^a	64.03±12.22^a

Please choose a citation manager

Content to export